Please login to the form below

Not currently logged in
Email:
Password:

Fabry disease

This page shows the latest Fabry disease news and features for those working in and with pharma, biotech and healthcare.

Chiesi launches new rare disease R&D division

Chiesi launches new rare disease R&D division

Chiesi already markets rare disease therapy Lamzede (velmanase alfa), which is approved by the European Medicines Agency for the treatment of patients with mild to moderate alpha-mannosidosis. ... In 2018, Chiesi also acquired the rights to commercialise

Latest news

More from news
Approximately 4 fully matching, plus 31 partially matching documents found.

Latest Intelligence

  • The trials and tribulations of rare opportunities The trials and tribulations of rare opportunities

    Revenue for Fabrazyme for treating Fabry disease, which affects 5, 000 people worldwide, was $891m. ... Patient-centricity is also core to Pfizer’s rare disease recruitment strategy, said Brownrigg.

  • Pharma deals in August 2015 Pharma deals in August 2015

    380 which will be used to treat cachexia, a wasting disease seen in cancer patients. ... Acquisition of remaining rights. 1034. Scioderm. Amicus. Galafold [migalastat] for Fabry's disease.

  • Pharma deals during November 2013 Pharma deals during November 2013

    A perfect strategic fit, this addition will create a $2bn rare disease revenue base in 2014, approx. ... Firstly, GSK decided to return rights to the experimental Fabry disease drug migalastat, noting that support would continue through GSK's equity

  • Payer focus in the personalised world of oncology and orphan diseases Payer focus in the personalised world of oncology and orphan diseases

    Personalised medicine is transforming disease understanding and many traditional diagnoses may be fundamentally revised based on the new scientific understanding. ... The Netherlands recently tried to withdraw public funding for late onset Fabry Disease

More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.

Latest appointments

  • Sobi names Holly May VP of sales and marketing, US Sobi names Holly May VP of sales and marketing, US

    Rare disease firm Sobi has appointed Holly May as its new vice president of sales and marketing for the US. ... May has had more than 20 years’ experience in biopharmaceutical sales and marketing, with her most recent role serving as head of US

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

  • Focus on Rare Diseases

    As pharma becomes more focused on rare disease therapies, Lucid Group recognises that medical education agencies need to respond. ... Lucid’s Rare Disease Business Unit currently works with clients in Fabry disease, Pompe disease, Gaucher disease,

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Cuttsy + Cuttsy

How do you understand what patients really need, without actually living their lives? How do you walk in someone else’s...

Latest intelligence

The concordance conundrum: understanding the complexities of behaviour change
Understanding behaviour change looks at the six fundamental steps required to change human behaviour and discusses why HCPs need to start here if concordance is to be improved....
The concordance conundrum: creating space for open dialogue
Growing numbers of patients want a partnership model with their HCP, whereby both parties are equally involved in the decision-making process. This model has been linked with an increase in...
Switzerland
Switzerland: a life sciences hub
Switzerland has a rich diversity of pharma and biotech companies that sustain activity and help maintain its reputation as a highly innovative country...

Infographics